Literature DB >> 26411806

Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.

James T Kearns1, Brittany Lapin2, Edward Wang2, Kimberly A Roehl3, Phillip Cooper3, William J Catalona3, Brian T Helfand2.   

Abstract

BACKGROUND: Associations have been documented recently between some of the 23 single nucleotide polymorphisms newly discovered with the Collaborative Oncological Gene-environment Study iCOGS array that indicate prostate cancer (PCa) risk and aspects of disease aggressiveness. The utility of these iCOGS SNPs remains to be determined in active surveillance (AS).
OBJECTIVE: To determine associations between iCOGS SNPs and upgrading among men who underwent surgical treatment and AS for low-risk PCa. DESIGN, SETTING, AND PARTICIPANTS: The genotypes of the 23 iCOGS SNPs were determined for all white subjects with biopsy Gleason score (GS) 6 including 950 men who underwent definitive treatment with surgery and 209 men who elected AS. The clinical and pathologic characteristics were documented for all subjects. OUTCOME MEASURES AND STATISTICAL ANALYSIS: Men who underwent surgery were grouped according to their pathologic GS (upgraded was defined as GS ≥7; nonupgraded remained GS 6). Men who were enrolled in AS were also grouped according to their GS on subsequent surveillance biopsies. Statistical analyses were performed comparing the genotypes between the upgraded and nonupgraded groups. RESULTS AND LIMITATIONS: Overall, 31% and 34% of men were upgraded in the surgery and AS cohorts, respectively. Three iCOGS SNPs were significantly associated with the risk of upgrading in the surgical cohort. After correction for multiple testing, only rs11568818 on chromosome 11q22 remained significantly associated with upgrading. Assessment of this allele in the AS cohort reveals that it was present at noteworthy higher frequencies in men with high-grade disease on surveillance biopsies compared with nonupgraded men (p=0.003). This study was primarily limited by the homogeneous patient population.
CONCLUSIONS: This is the first report of a SNP on chromosome 11q22 associated with higher grade disease in a surgical cohort that is also validated for eventual upgrading in a prospective AS cohort. PATIENT
SUMMARY: We examined the relationship between a group of genetic markers and prostate cancer (PCa) aggressiveness in a group of patients who underwent surgery for PCa and a group of patients who were enrolled in active surveillance. We found that these genetic markers helped predict which patients had more aggressive disease in both groups.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Genetics; Prostate cancer; Single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26411806      PMCID: PMC4885743          DOI: 10.1016/j.eururo.2015.09.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

2.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.

Authors:  Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon T Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel Gudbjartsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Andrew D Morris; Charlotte H Kimber; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Wing-Yee So; Peter C Y Tong; Maggie C Y Ng; Torben Hansen; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Alejandro Tres; Fernando Fuertes; Manuel Ruiz-Echarri; Laura Asin; Berta Saez; Erica van Boven; Siem Klaver; Dorine W Swinkels; Katja K Aben; Theresa Graif; John Cashy; Brian K Suarez; Onco van Vierssen Trip; Michael L Frigge; Carole Ober; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Colin N A Palmer; Charles Rotimi; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Rafn Benediktsson; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; William J Catalona; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

3.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

4.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.

Authors:  Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian L Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

5.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.

Authors:  E W Steyerberg; M J Roobol; M W Kattan; T H van der Kwast; H J de Koning; F H Schröder
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

6.  Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.

Authors:  Jielin Sun; Bao-Li Chang; Sarah D Isaacs; Kathleen E Wiley; Fredrik Wiklund; Pär Stattin; David Duggan; John D Carpten; Bruce J Trock; Alan W Partin; Patrick C Walsh; Henrik Grönberg; Jianfeng Xu; William B Isaacs; S Lilly Zheng
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

7.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.

Authors:  Michael W Kattan; James A Eastham; Thomas M Wheeler; Norio Maru; Peter T Scardino; Andreas Erbersdobler; Markus Graefen; Hartwig Huland; Hideshige Koh; Shahrokh F Shariat; Kevin M Slawin; Makoto Ohori
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

8.  Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.

Authors:  Felix K-H Chun; Alexander Haese; Sascha A Ahyai; Jochen Walz; Nazareno Suardi; Umberto Capitanio; Markus Graefen; Andreas Erbersdobler; Hartwig Huland; Pierre I Karakiewicz
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

9.  Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior.

Authors:  B J Grindel; J R Martinez; C L Pennington; M Muldoon; J Stave; L W Chung; M C Farach-Carson
Journal:  Matrix Biol       Date:  2014-05-14       Impact factor: 11.583

10.  A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.

Authors:  Hiroyuki Nakanishi; Xuemei Wang; Atsushi Ochiai; Kiril Trpkov; Asli Yilmaz; J Bryan Donnelly; John W Davis; Patricia Troncoso; R Joseph Babaian
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

View more
  10 in total

1.  Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.

Authors:  A Sanchez; J D Schoenfeld; P L Nguyen; M Fiorentino; D Chowdhury; M J Stampfer; H D Sesso; E Giovannucci; L A Mucci; I M Shui
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-01       Impact factor: 5.554

2.  Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Authors:  Qinchuan Wang; Justin R Gregg; Jian Gu; Yuanqing Ye; David W Chang; John W Davis; Timothy C Thompson; Jeri Kim; Christopher J Logothetis; Xifeng Wu
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

Review 3.  A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).

Authors:  Sarah Benafif; Zsofia Kote-Jarai; Rosalind A Eeles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01-18       Impact factor: 4.254

4.  Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.

Authors:  Xiang Shu; Yuanqing Ye; Jian Gu; Yonggang He; John W Davis; Timothy C Thompson; Christopher J Logothetis; Jeri Kim; Xifeng Wu
Journal:  Carcinogenesis       Date:  2016-08-11       Impact factor: 4.944

5.  Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.

Authors:  Carly A Conran; Rong Na; Haitao Chen; Deke Jiang; Xiaoling Lin; S Lilly Zheng; Charles B Brendler; Jianfeng Xu
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

6.  Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

Authors:  Salpie Nowinski; Aida Santaolalla; Ben O'Leary; Massimo Loda; Ayesha Mirchandani; Mark Emberton; Mieke Van Hemelrijck; Anita Grigoriadis
Journal:  Oncotarget       Date:  2018-02-05

Review 7.  Active surveillance for intermediate-risk prostate cancer.

Authors:  M A Dall'Era; L Klotz
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-11-01       Impact factor: 5.554

Review 8.  Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance.

Authors:  Zachary A Glaser; Jennifer B Gordetsky; Kristin K Porter; Sooryanarayana Varambally; Soroush Rais-Bahrami
Journal:  Front Oncol       Date:  2017-10-30       Impact factor: 6.244

9.  Personalized prostate cancer care: from screening to treatment.

Authors:  Carly A Conran; Charles B Brendler; Jianfeng Xu
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

10.  Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.

Authors:  Xinming Han; Yan Han; Yongsheng Zheng; Qiang Sun; Tao Ma; Li Dai; Junyi Zhang; Lianji Xu
Journal:  Onco Targets Ther       Date:  2018-02-05       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.